Palisade Bio Gains Health Canada Clearance for Phase 2 Ulcerative…

Event summary

Health Canada cleared Palisade Bio's Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study of PALI-2108 in ulcerative colitis patients.
The clearance enables site activation and enrollment in Canada, expanding the study's geographic reach.
Primary efficacy results from approximately 204 patients are expected in the second half of 2027.
PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon.

The big picture

Palisade Bio's expansion into Canada for its Phase 2 trial of PALI-2108 aligns with broader industry trends of globalizing clinical research to accelerate development timelines and enhance patient access. The study's focus on once-daily oral dosing and targeted activation addresses a critical need in the inflammatory bowel disease market, where current therapies often fall short in providing durable remission.

What we're watching

Execution Risk: Whether Palisade Bio can efficiently activate sites and enroll patients across global locations to meet the 2027 efficacy results timeline.
Clinical Efficacy: How the once-daily oral dosing and targeted activation of PALI-2108 will translate into clinical remission and mucosal improvement in ulcerative colitis patients.
Market Dynamics: The pace at which Palisade Bio can differentiate PALI-2108 in a competitive landscape where many patients with ulcerative colitis do not achieve durable remission.